Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds SLART to AB, MCLM, and TI fields

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:50:04 ON 07 JUL 2009

=> file registry
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.22   0.22

FILE 'REGISTRY' ENTERED AT 10:50:22 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2009 HIGHEST RN 1160908-15-5
DICTIONARY FILE UPDATES: 6 JUL 2009 HIGHEST RN 1160908-15-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10599121_elected.str



chain nodes :
10 23 24 25 26
ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
1-25 2-26 7-11 7-12 8-10 15-23 20-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-13 11-17 12-18 12-22 13-14
 14-15 15-16 16-17 18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 15-23 20-24
exact bonds :
1-25 2-26 7-11 7-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 12-18 12-22 13-14 14-15 15-16
16-17 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss
SAMPLE SEARCH INITIATED 10:50:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6 TO ITERATE

100.0% PROCESSED   6 ITERATIONS   0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 6 TO   266
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:50:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   167 TO ITERATE

100.0% PROCESSED   167 ITERATIONS   3 ANSWERS
SEARCH TIME: 00.00.01

L3   3 SEA SSS FUL L1

=> d l3 1-3

L3   ANSWER 1 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN   1073261-21-8 REGISTRY
ED   Entered STN: 19 Nov 2008
CN   2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-2-methylphenyl)-3-(4-
     hydroxyphenyl)- (CA INDEX NAME)
MF   C21 H15 F2 N O3
SR   CA
LC   STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 2 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN   1073261-20-7 REGISTRY
ED   Entered STN: 19 Nov 2008
CN   2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3-(4-hydroxy-3-methylphenyl)-3-(4-
     hydroxyphenyl)- (CA INDEX NAME)
MF   C21 H15 F2 N O3
SR   CA
LC   STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2009 ACS on STN
RN 867154-86-7 REGISTRY
ED Entered STN: 10 Nov 2005
CN 2H-Indol-2-one, 6,7-difluoro-1,3-dihydro-3,3-bis(4-hydroxyphenyl)- (CA INDEX NAME)
MF C20 H13 F2 N O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.03	192.25

FILE 'CAPLUS' ENTERED AT 10:51:06 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Jul 2009 VOL 151 ISS 2
FILE LAST UPDATED: 6 Jul 2009 (20090706/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4   4 L3

=> d l4 1-4 ibib, abs

L4   ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1299768 CAPLUS
DOCUMENT NUMBER: 149:513691
TITLE: Preparation of 3-(4-hydroxyphenyl)-indolin-2-ones for
                         the treatment of cancer
INVENTOR(S):   Christensen, Mette Knak; Bjoerkling, Fredrik
PATENT ASSIGNEE(S):   Topotarget A/S, Den.
SOURCE: PCT Int. Appl., 123pp.
                         CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008129075	A1	20081030	WO 2008-EP54990	20080424
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-913625P P 20070424
OTHER SOURCE(S): MARPAT 149:513691
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [r = 0 or 1; X = -CH2-, -O-, -S-, etc.; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted alkenyl, etc.; V1-V4 = carbon atom, non-quaternary nitrogen atom, oxygen atom, etc.; R1-R4, when attached to a carbon atom, are independently H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R1-R4, when attached to a nitrogen atom, are independently H, (un)substituted alkyl, hydroxy, etc.; R1 and R2 together with the carbon atoms to which they attached may form a ring; with the proviso that at least one of R1-R4 is not H] and pharmaceutically acceptable salts and prodrugs thereof were prepared For example, compound II was prepared by following general procedure: treatment of 3-substituted-3-hydroxy-indolin-2-one with phenol (5.0 equiv) and p-TsOH (7.5 equiv) in dichloroethane at 90° for 2-4 h. In cell proliferation assay (WST assay) using MCF-7, the IC50 of compound II was 3.4 nM.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:733160 CAPLUS

DOCUMENT NUMBER: 149:53867

TITLE: Preparation of prodrugs of 3,3-diphenyl-1,3-dihydroindol-2-one for the treatment of cancer

INVENTOR(S): Christensen, Mette Knak; Bjoerkling, Fredrik; Ikaunieks, Martins; Zaichenko, Andrei; Gailite, Vija; Loza, Einars; Kalvinsh, Ivars; Madre, Marina

PATENT ASSIGNEE(S): Topotarget A/S, Den.

SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008071387	A1	20080619	WO 2007-EP10805	20071211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-869428P P 20061211

OTHER SOURCE(S): MARPAT 149:53867

GI



I

AB Title compds. [I; X1, X2 = prodrug group; Rn = prodrug group, H, OH, (substituted) alkyl, alkoxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, etc.; V1-V4 = C, N, O, S, bond; R1-R4 = H, OH, NO2, halo, (substituted) alkyl, alkoxy, alkenyl, alkenyloxy, alkoxycarbonyl, alkylthio, aryl, heterocyclyl, etc.; R1R2 = atoms to form a ring; with provisos], were prepared as anticancer drugs (no data). Thus, 6,7-difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-1,3-dihydroindol-2-one and Boc-Ala-OH were coupled using EDC and DMAP in CH2Cl2 followed by deprotection with HCl in Et2O to give (2S)-4-(6,7-difluoro-3-(4-methoxyphenyl)-2-oxoindolin-3-yl)phenyl 2-aminopropanoate hydrochloride.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:478005 CAPLUS

DOCUMENT NUMBER: 147:95492

TITLE: Syntheses and antiproliferative evaluation of oxyphenisatin derivatives

AUTHOR(S): Uddin, Muhammed K.; Reignier, Serge G.; Coulter, Tom; Montalbetti, Christian; Granaes, Charlotta; Butcher, Steven; Krog-Jensen, Christian; Felding, Jakob

CORPORATE SOURCE: Evotec(UK) Ltd., Abingdon, Oxon, OX14 4RX, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2854-2857
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:95492

GI



I



II

AB Syntheses and structure-antiproliferative relationship for oxyphenisatin analogs are described. The cell proliferation data showed that the presence of substituents (especially F, Cl, Me, CF3, and OMe) in the 6- and 7-position of oxyphenisatin markedly enhanced the potency in the MDA-468 cell line without affecting the MDA-231 cell line. The best compds. I and II showed low nanomolar antiproliferative activity towards the MDA-468 cell line and a 1000-fold selectivity over the MDA-231 cell line.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1123755 CAPLUS

DOCUMENT NUMBER: 143:405798

TITLE: Preparation of 3,3-diphenyl-indol-2-one derivatives as anticancer agents

INVENTOR(S): Felding, Jakob; Pedersen, Hans Christian; Krog-Jensen, Christian; Praestegaard, Morten; Butcher, Steven Peter; Linde, Viggo; Coulter, Thomas Stephen; Montalbetti, Christian; Uddin, Mohammed; Reignier, Serge

PATENT ASSIGNEE(S): Biolmage A/S, Den.

SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097107	A2	20051020	WO 2005-DK244	20050408
WO 2005097107	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, SI, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005230232	A1	20051020	AU 2005-230232	20050408
CA 2562399	A1	20051020	CA 2005-2562399	20050408
EP 1734951	A2	20061227	EP 2005-715161	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1953747	A	20070425	CN 2005-80010250	20050408
BR 2005009745	A	20070925	BR 2005-9745	20050408
JP 2007532496	T	20071115	JP 2007-506660	20050408
MX 2006010822	A	20061120	MX 2006-10822	20060921
ZA 2006008044	A	20080130	ZA 2006-8044	20060927
IN 2006KN03070	A	20070608	IN 2006-KN3070	20061023
NO 2006005034	A	20061102	NO 2006-5034	20061102
KR 2006130781	A	20061219	KR 2006-723439	20061108
US 20070299102	A1	20071227	US 2007-599121	20070601
PRIORITY APPLN. INFO.:			DK 2004-576 A	20040408

	DK 2004-693	A	20040501
	DK 2004-1153	A	20040727
	DK 2004-1216	A	20040811
	WO 2005-DK244	W	20050408

OTHER SOURCE(S): MARPAT 143:405798
GI



I

AB Title compds. represented by the formula I [R1 = H, halo, alkyl, etc.; R2 = H, halo, (un)substituted aryl, etc.; R3 = H, (un)substituted alkoxy, halo, etc.; Z = CH or N; X1, X2 = independently halo, amino, aminosulfonylalkyl, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as anticancer agents. For example, 6-chloro-3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-indol-2-one (II) was provided in a multi-step synthesis starting from 2-methyl-3-chloroaniline. I showed inhibition of proliferation of MDA-468 human breast cancer cells at lower concns., and II was tested in protein synthesis, translation control, PC3M human prostate cancer cell and etc. Thus, I and their pharmaceutical compns. are useful for the treatment of cancers in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth, such as human breast cancer and prostate cancer.

=> d his

(FILE 'HOME' ENTERED AT 10:50:04 ON 07 JUL 2009)

FILE 'REGISTRY' ENTERED AT 10:50:22 ON 07 JUL 2009
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS
L3 3 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:51:06 ON 07 JUL 2009
L4 4 S L3

=> file medline biosis embase

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.50	204.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.28	-3.28

FILE 'MEDLINE' ENTERED AT 10:51:50 ON 07 JUL 2009

FILE 'BIOSIS' ENTERED AT 10:51:50 ON 07 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:51:50 ON 07 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s l3<chem>

   SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.21	207.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.28

FILE 'REGISTRY' ENTERED AT 10:51:55 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L3 1- CHEM
L5   SEL L3 1- CHEM :   3 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.08	223.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.28

FILE 'MEDLINE' ENTERED AT 10:51:55 ON 07 JUL 2009

FILE 'BIOSIS' ENTERED AT 10:51:55 ON 07 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:51:55 ON 07 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

S L5
L6   0 L5

=> s l3
L7   0 L3

=> d his

     (FILE 'HOME' ENTERED AT 10:50:04 ON 07 JUL 2009)

```
     FILE 'REGISTRY' ENTERED AT 10:50:22 ON 07 JUL 2009
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS
L3            3 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:51:06 ON 07 JUL 2009
L4            4 S L3

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:50 ON 07 JUL 2009

     FILE 'REGISTRY' ENTERED AT 10:51:55 ON 07 JUL 2009
                SET SMARTSELECT ON
L5          SEL L3 1- CHEM :       3 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:55 ON 07 JUL 2009
L6            0 S L5
L7            0 S L3

=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   3.39     226.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00      -3.28

FILE 'REGISTRY' ENTERED AT 10:52:41 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JUL 2009  HIGHEST RN 1160908-15-5
DICTIONARY FILE UPDATES:   6 JUL 2009  HIGHEST RN 1160908-15-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10599121_genus.str
```



chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
7-11 7-12 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-13 11-17 12-18 12-22 13-14
14-15 15-16 16-17 18-19 19-20 20-21 21-22
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10
exact bonds :
7-11 7-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-13 11-17 12-18 12-22 13-14 14-15 15-16
16-17 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l8 sss
SAMPLE SEARCH INITIATED 10:52:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      213 TO ITERATE

100.0% PROCESSED      213 ITERATIONS                              41 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3385 TO     5135
PROJECTED ANSWERS:             436 TO     1204

L9           41 SEA SSS SAM L8

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.48     226.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.28

FILE 'CAPLUS' ENTERED AT 10:53:11 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 7 Jul 2009 VOL 151 ISS 2
FILE LAST UPDATED: 6 Jul 2009 (20090706/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l9
L10   54 L9

=> s l10 and (?cancer? or ?tumour? or ?tumor? or ?neoplasm?)
        460598 ?CANCER?
          6357 ?TUMOUR?
        730905 ?TUMOR?
        730905 ?TUMOR?
        731273 ?TUMOUR?
                 (?TUMOUR? OR ?TUMOR?)
        730905 ?TUMOR?
          6357 ?TUMOUR?
          6357 ?TUMOUR?
        731273 ?TUMOR?
                 (?TUMOR? OR ?TUMOUR?)
        568983 ?NEOPLASM?
L11   5 L10 AND (?CANCER? OR ?TUMOUR? OR ?TUMOR? OR ?NEOPLASM?)

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12   5 DUP REM L11 (0 DUPLICATES REMOVED)

=> d l12 1-5 ibib, abs

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:733160 CAPLUS
DOCUMENT NUMBER: 149:53867
TITLE: Preparation of prodrugs of
                         3,3-diphenyl-1,3-dihydroindol-2-one for the treatment
                         of cancer
INVENTOR(S):   Christensen, Mette Knak; Bjoerkling, Fredrik;
                         Ikaunieks, Martins; Zaichenko, Andrei; Gailite, Vija;
                         Loza, Einars; Kalvinsh, Ivars; Madre, Marina
PATENT ASSIGNEE(S):   Topotarget A/S, Den.
SOURCE: PCT Int. Appl., 85pp.
                         CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO.   DATE
     ---------------   ----   --------   --------------------   --------
     WO 2008071387   A1   20080619   WO 2007-EP10805   20071211
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-869428P P 20061211

OTHER SOURCE(S): MARPAT 149:53867

GI



I

AB Title compds. [I; X1, X2 = prodrug group; Rn = prodrug group, H, OH, (substituted) alkyl, alkoxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, etc.; V1-V4 = C, N, O, S, bond; R1-R4 = H, OH, NO2, halo, (substituted) alkyl, alkoxy, alkenyl, alkenyloxy, alkoxycarbonyl, alkylthio, aryl, heterocyclyl, etc.; R1R2 = atoms to form a ring; with provisos], were prepared as anticancer drugs (no data). Thus, 6,7-difluoro-3-(4-hydroxyphenyl)-3-(4-methoxyphenyl)-1,3-dihydroindol-2-one and Boc-Ala-OH were coupled using EDC and DMAP in CH2Cl2 followed by deprotection with HCl in Et2O to give (2S)-4-(6,7-difluoro-3-(4-methoxyphenyl)-2-oxoindolin-3-yl)phenyl 2-aminopropanoate hydrochloride.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:478005 CAPLUS

DOCUMENT NUMBER: 147:95492

TITLE: Syntheses and antiproliferative evaluation of oxyphenisatin derivatives

AUTHOR(S): Uddin, Muhammed K.; Reignier, Serge G.; Coulter, Tom; Montalbetti, Christian; Granaes, Charlotta; Butcher, Steven; Krog-Jensen, Christian; Felding, Jakob

CORPORATE SOURCE: Evotec(UK) Ltd., Abingdon, Oxon, OX14 4RX, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2854-2857
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:95492

GI



I



II

AB Syntheses and structure-antiproliferative relationship for oxyphenisatin analogs are described. The cell proliferation data showed that the presence of substituents (especially F, Cl, Me, CF3, and OMe) in the 6- and 7-position of oxyphenisatin markedly enhanced the potency in the MDA-468 cell line without affecting the MDA-231 cell line. The best compds. I and II showed low nanomolar antiproliferative activity towards the MDA-468 cell line and a 1000-fold selectivity over the MDA-231 cell line.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1123755 CAPLUS

DOCUMENT NUMBER: 143:405798

TITLE: Preparation of 3,3-diphenyl-indol-2-one derivatives as anticancer agents

INVENTOR(S): Felding, Jakob; Pedersen, Hans Christian; Krog-Jensen, Christian; Praestegaard, Morten; Butcher, Steven Peter; Linde, Viggo; Coulter, Thomas Stephen; Montalbetti, Christian; Uddin, Mohammed; Reignier, Serge

PATENT ASSIGNEE(S): Biolmage A/S, Den.

SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097107	A2	20051020	WO 2005-DK244	20050408
WO 2005097107	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, SI, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005230232	A1	20051020	AU 2005-230232		20050408
CA 2562399	A1	20051020	CA 2005-2562399		20050408
EP 1734951	A2	20061227	EP 2005-715161		20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1953747	A	20070425	CN 2005-80010250		20050408
BR 2005009745	A	20070925	BR 2005-9745		20050408
JP 2007532496	T	20071115	JP 2007-506660		20050408
MX 2006010822	A	20061120	MX 2006-10822		20060921
ZA 2006008044	A	20080130	ZA 2006-8044		20060927
IN 2006KN03070	A	20070608	IN 2006-KN3070		20061023
NO 2006005034	A	20061102	NO 2006-5034		20061102
KR 2006130781	A	20061219	KR 2006-723439		20061108
US 20070299102	A1	20071227	US 2007-599121		20070601
PRIORITY APPLN. INFO.:			DK 2004-576	A	20040408
			DK 2004-693	A	20040501
			DK 2004-1153	A	20040727
			DK 2004-1216	A	20040811
			WO 2005-DK244	W	20050408

OTHER SOURCE(S): MARPAT 143:405798

GI



I

AB Title compds. represented by the formula I [R1 = H, halo, alkyl, etc.; R2 = H, halo, (un)substituted aryl, etc.; R3 = H, (un)substituted alkoxy, halo, etc.; Z = CH or N; X1, X2 = independently halo, amino, aminosulfonylalkyl, etc.; and pharmaceutically acceptable salts or prodrugs thereof] were prepared as anticancer agents. For example, 6-chloro-3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-indol-2-one (II) was provided in a multi-step synthesis starting from 2-methyl-3-chloroaniline. I showed inhibition of proliferation of MDA-468 human breast cancer cells at lower concns., and II was tested in protein synthesis, translation control, PC3M human prostate cancer cell and etc. Thus, I and their pharmaceutical compns. are useful for the treatment of cancers in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth, such as human breast cancer and prostate cancer.

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:962211 CAPLUS

DOCUMENT NUMBER: 143:266816

TITLE: Preparation of 3-3-di-substituted oxindoles as inhibitors of translation initiation

INVENTOR(S): Halperin, Jose A.; Natarajan, Amarnath; Aktas, Huseyin; Fan, Yun-Hua; Chen, Han

PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080335	A1	20050901	WO 2005-US4373	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005214338	A1	20050901	AU 2005-214338	20050211
CA 2555812	A1	20050901	CA 2005-2555812	20050211
EP 1718611	A1	20061108	EP 2005-722960	20050211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007522234	T	20070809	JP 2006-553263	20050211
US 20070099976	A1	20070503	US 2006-463421	20060809
PRIORITY APPLN. INFO.:			US 2004-544384P P	20040213
			WO 2005-US4373 W	20050211

OTHER SOURCE(S): CASREACT 143:266816; MARPAT 143:266816
GI



I



II

AB A compds. I [A = carbocyclic aromatic, heterocyclic and heteroarom. ring; R1 = haloalkyl, (un)substituted (alkyl)aryl, halogen, CN, CO2H, alkenyl, alkynyl, alkoxy and cycloalkyl; R2, R3 and R4 = independently (un)substituted aryl, heterocyclic, heteroarom., Ar-NHSO2Ar and Ar-NHCO-Ar; X and Y = independently (un)substituted N, O, S and C; n = 0-4] were prepared as inhibitors of translation initiation for treating of cellular proliferative disorder in a human and non-human mammals. Thus,

compound II was prepared by condensation of 3-bromoaniline with hydroxylamine hydrochloride and chloral hydrate, following by cyclization and phenylation, and showed pos. calcium release from intracellular stores and IC50 = 8 for lung cancer cell growth inhibition.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:189011 CAPLUS
DOCUMENT NUMBER: 140:391175
TITLE: 3,3-Diaryl-1,3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition
AUTHOR(S): Natarajan, Amarnath; Fan, Yun-Hua; Chen, Han; Guo, Yuhong; Iyasere, Julia; Harbinski, Frederick; Christ, William J.; Aktas, Huseyin; Halperin, Jose A.
CORPORATE SOURCE: Laboratory for Translational Research, Harvard Medical School, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(8), 1882-1885
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:391175
AB A series of substituted 3,3-diphenyl-1,3-dihydroindol-2-ones was synthesized from the corresponding isatins. The compds. were studied for cell growth inhibition mediated by partial depletion of intracellular Ca2+ stores that leads to phosphorylation of eIF2α. 3,3-Diphenyloxindole showed mechanism-specific antiproliferative activity that was comparable to known translation initiation inhibitors such as clotrimazole or troglitazone. SAR studies identified 3-(5-tert.-butyl-2-hydroxyphenyl)-3-phenyloxindole as a lead compound for Ca2+-depletion-mediated inhibition of translation initiation.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:50:04 ON 07 JUL 2009)

FILE 'REGISTRY' ENTERED AT 10:50:22 ON 07 JUL 2009
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS
L3 3 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:51:06 ON 07 JUL 2009
L4 4 S L3

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:50 ON 07 JUL 2009

FILE 'REGISTRY' ENTERED AT 10:51:55 ON 07 JUL 2009
SET SMARTSELECT ON
L5 SEL L3 1- CHEM : 3 TERMS
SET SMARTSELECT OFF

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:55 ON 07 JUL 2009
L6 0 S L5
L7 0 S L3

FILE 'REGISTRY' ENTERED AT 10:52:41 ON 07 JUL 2009

```
L8              STRUCTURE UPLOADED
L9           41 S L8 SSS

     FILE 'CAPLUS' ENTERED AT 10:53:11 ON 07 JUL 2009
L10          54 S L9
L11           5 S L10 AND (?CANCER? OR ?TUMOUR? OR ?TUMOR? OR ?NEOPLASM?)
L12           5 DUP REM L11 (0 DUPLICATES REMOVED)

=> file medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      25.46     252.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.10      -7.38

FILE 'MEDLINE' ENTERED AT 10:54:54 ON 07 JUL 2009

FILE 'BIOSIS' ENTERED AT 10:54:54 ON 07 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:54:54 ON 07 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> s l9<chem>

   SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.21     255.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.38

FILE 'REGISTRY' ENTERED AT 10:55:00 ON 07 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L9 1- CHEM
L13          SEL L9 1- CHEM :      57 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.08     270.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.38
```

FILE 'MEDLINE' ENTERED AT 10:55:08 ON 07 JUL 2009

FILE 'BIOSIS' ENTERED AT 10:55:08 ON 07 JUL 2009

FILE 'EMBASE' ENTERED AT 10:55:08 ON 07 JUL 2009

S L13
L14 15 L13

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15 9 DUP REM L14 (6 DUPLICATES REMOVED)

=> d l15 1-9 ibib, abs

L15 ANSWER 1 OF 9 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 1983047299 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7138083
TITLE: Fate and excretion of sodium sulisatin in the rat.
AUTHOR: Moreto M; Gonalons E; Giraldez A; Torralba A
SOURCE: Archivos de farmacologia y toxicologia, (1982 Apr) Vol. 8, No. 1, pp. 21-8.
Journal code: 7601472. ISSN: 0304-8616.
PUB. COUNTRY: Spain
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198212
ENTRY DATE: Entered STN: 17 Mar 1990
Last Updated on STN: 17 Mar 1990
Entered Medline: 21 Dec 1982

L15 ANSWER 2 OF 9 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 1980087889 MEDLINE
DOCUMENT NUMBER: PubMed ID: 583222
TITLE: 3,3-Bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the active metabolite of the laxative sulisatin.
AUTHOR: Moreto M; Gonalons E; Mylonakis N; Giraldez A; Torralba A
SOURCE: Arzneimittel-Forschung, (1979) Vol. 29, No. 10, pp. 1561-4.
Journal code: 0372660. ISSN: 0004-4172.
PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of
DOCUMENT TYPE: (IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198002
ENTRY DATE: Entered STN: 15 Mar 1990
Last Updated on STN: 15 Mar 1990
Entered Medline: 28 Feb 1980
AB The disodium salt of the sulphuric diester of 3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (sodium sulisatin, Laxitex), a synthetic laxative with two phenolic groups esterified with sulfate, has been studied in order to find out if its laxative properties may be attributed to the unaltered compound or to its diphenolic derivative BHMI. We first studied the effect of homogenates of the gastrointestinal tract of rats and of rat cecal content of the hydrolysis of sulfate ester bonds of sulisatin. Results show that sulisatin can be hydrolyzed by cecal content while homogenates of stomach,

small intestine and large intestine have no hydrolytic effect. Sulisatin is also a substrate of arylsulfate sulphohydrolase obtained from the snail Helix pomatia. The unaltered drug has no effect on the intestinal motility since it does not change the intestinal transit speed in rats pretreated with neomycin sulfate. Sulisatin (1.5, 3 and 6 mg) is unable to inhibit water absorption in rat colon while small amounts of BHMI (15 and 30 micrograms) may inhibit it significantly. It is concluded that sulisatin passes unaltered through the small intestine and is hydrolyzed in the large intestine by the intestinal microflora to its diphenolic derivative BHMI, which is responsible for the laxative activity of the drug.

L15 ANSWER 3 OF 9 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 1980:184759 BIOSIS
DOCUMENT NUMBER: PREV198069059755; BA69:59755
TITLE: OXYPHENISATIN DERIVATIVES AND INTESTINAL GLUCOSE AND TYROSINE ABSORPTION.
AUTHOR(S): DE CASTELLARNAU C [Reprint author]; MORETO M
CORPORATE SOURCE: FAC FARM, UNIV BARCELONA, BARCELONA-28, SPAIN
SOURCE: Revista Espanola de Fisiologia, (1979) Vol. 35, No. 3, pp. 327-330.
CODEN: REFIAS. ISSN: 0034-9402.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
AB The effect of oxyphenisatin and 3 other isatin derivatives [sodium sulphatin, bis-(p-hydroxyphenyl)-7-methyl-2-indolinone and sodium sulisatin] on glucose and Tyr absorption was studied in rat small intestine in vitro. Compounds with free phenolic groups, even at low concentrations, strongly inhibited active transport, while those with the sulfate-esterified phenolic groups showed no effect. One min preincubation with 10-3 M oxyphenisatin inhibited sugar absorption completely.

L15 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 1977251890 MEDLINE
DOCUMENT NUMBER: PubMed ID: 19589
TITLE: Enterohepatic circulation of sodium sulisatin and its effects on glucose absorption in the rat.
AUTHOR: Moreto M; Gonalons E; Mylonakis N; Giraldez A; Torralba A
SOURCE: The Journal of pharmacy and pharmacology, (1977 Jul) Vol. 29, No. 7, pp. 446-8.
Journal code: 0376363. ISSN: 0022-3573.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197710
ENTRY DATE: Entered STN: 14 Mar 1990
Last Updated on STN: 6 Feb 1995
Entered Medline: 14 Oct 1977

L15 ANSWER 5 OF 9 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
ACCESSION NUMBER: 1978:47506 BIOSIS
DOCUMENT NUMBER: PREV197814047506; BR14:47506
TITLE: SULISATINE SODIUM.
AUTHOR(S): GARRIDO F
SOURCE: Drugs of Today, (1977) Vol. 13, No. 8, pp. 327-338.
CODEN: MDACAP. ISSN: 0025-7656.
DOCUMENT TYPE: Article
FILE SEGMENT: BR

LANGUAGE: Unavailable

L15 ANSWER 6 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1976165409 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1261595
TITLE: Study of the laxative properties of the disodium salt of the sulfuric diester of 3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (DAN-603 in the rat.
AUTHOR: Moreto M; Gonalons E; Giraldez A; Torralba A
SOURCE: European journal of pharmacology, (1976 Mar) Vol. 36, No. 1, pp. 223-6.
Journal code: 1254354. ISSN: 0014-2999.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197607
ENTRY DATE: Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990
Entered Medline: 6 Jul 1976
AB The influence of DAN-603 (disodium salt of sulphuric diester of 3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone) on the propulsive motility of the rat digestive tract was studied by means of indicators (charcoal and pyrvinium pamoate) and radioactive tracers (133BaSO4). The results showed that DAN-603 increases selectively the colon motility without modifying the speed of gastric, intestinal (small intestine) and caecal emptying.

L15 ANSWER 7 OF 9 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
DUPLICATE 4
ACCESSION NUMBER: 1976:191743 BIOSIS
DOCUMENT NUMBER: PREV197662021743; BA62:21743
TITLE: STUDY OF THE LAXATIVE PROPERTIES OF THE DI SODIUM SALT OF THE SULFURIC DI ESTER OF 3 3 BIS-4 HYDROXYPHENYL-7-METHYL-2 INDOLINONE DAN-603 IN THE RAT.
AUTHOR(S): MORETO M; GONALONS E; GIRALDEZ A; TORRALBA A
SOURCE: European Journal of Pharmacology, (1976) Vol. 36, No. 1, pp. 221-226.
CODEN: EJPHAZ. ISSN: 0014-2999.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: Unavailable

L15 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 1976230453 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1230028
TITLE: [The mechanism of the laxative action of DAN-603 (author's transl)].
Mecanismo de accion del DAN-603 sobre el funcionamiento intestinal.
AUTHOR: Anonymous
SOURCE: Archivos de farmacologia y toxicologia, (1975 Aug) Vol. 1, No. 2, pp. 137-46.
Journal code: 7601472. ISSN: 0304-8616.
PUB. COUNTRY: Spain
DOCUMENT TYPE: (ENGLISH ABSTRACT)
(IN VITRO)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Spanish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 197609

```
ENTRY DATE:          Entered STN: 13 Mar 1990
                     Last Updated on STN: 13 Mar 1990
                     Entered Medline: 2 Sep 1976

L15  ANSWER 9 OF 9  EMBASE  COPYRIGHT (c) 2009 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:    1977100370  EMBASE
TITLE:               [The mechanism of the laxative action of DAN
                     603].
                     MECANISMO DE ACCION DEL DAN 603 SOBRE
                     EL FUNCIONAMIENTO INTESTINAL.
AUTHOR:              Queralt, J.; Gonalons, E.; Giraldez, A.
CORPORATE SOURCE:    Dept. Invest., Lab. Andreu, Barcelona, Spain.
SOURCE:              ARCH.FARMACOL.TOXICOL., (1975) Vol. 1, No. 2, pp. 137-146.
                     CODEN: XXXXXB
DOCUMENT TYPE:       Journal
FILE SEGMENT:        030     Clinical and Experimental Pharmacology
                     037     Drug Literature Index
                     048     Gastroenterology
LANGUAGE:            Spanish; Castilian


=> d his

     (FILE 'HOME' ENTERED AT 10:50:04 ON 07 JUL 2009)

     FILE 'REGISTRY' ENTERED AT 10:50:22 ON 07 JUL 2009
L1                STRUCTURE UPLOADED
L2              0 S L1 SSS
L3              3 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:51:06 ON 07 JUL 2009
L4              4 S L3

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:50 ON 07 JUL 2009

     FILE 'REGISTRY' ENTERED AT 10:51:55 ON 07 JUL 2009
                   SET SMARTSELECT ON
L5            SEL L3 1- CHEM :       3 TERMS
                   SET SMARTSELECT OFF

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:51:55 ON 07 JUL 2009
L6              0 S L5
L7              0 S L3

     FILE 'REGISTRY' ENTERED AT 10:52:41 ON 07 JUL 2009
L8                STRUCTURE UPLOADED
L9             41 S L8 SSS

     FILE 'CAPLUS' ENTERED AT 10:53:11 ON 07 JUL 2009
L10            54 S L9
L11             5 S L10 AND (?CANCER? OR ?TUMOUR? OR ?TUMOR? OR ?NEOPLASM?)
L12             5 DUP REM L11 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:54:54 ON 07 JUL 2009

     FILE 'REGISTRY' ENTERED AT 10:55:00 ON 07 JUL 2009
                   SET SMARTSELECT ON
L13           SEL L9 1- CHEM :      57 TERMS
                   SET SMARTSELECT OFF

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:55:08 ON 07 JUL 2009
```

```
L14          15 S L13
L15           9 DUP REM L14 (6 DUPLICATES REMOVED)

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    14.88     285.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -7.38

STN INTERNATIONAL LOGOFF AT 10:55:45 ON 07 JUL 2009
```